Document Detail


A Randomised, Placebo-Controlled, Dose-Finding Study Of AZD9668, An Oral Inhibitor of Neutrophil Elastase, in Patients with Chronic Obstructive Pulmonary Disease Treated with Tiotropium.
MedLine Citation:
PMID:  22458939     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Abstract AZD9668 is a fully reversible, selective, oral inhibitor of neutrophil elastase, a protease implicated in chronic obstructive pulmonary disease (COPD). Efficacy, safety and tolerability of AZD9668 (5, 20 and 60 mg bid) were compared with placebo in a randomised, double-blind, placebo-controlled, 12-week, Phase IIb trial (NCT00949975: approved by an Investigational Review Board), in patients with symptomatic COPD receiving maintenance tiotropium. The primary endpoint was pre-bronchodilator forced expiratory volume in 1 second (FEV1). Secondary endpoints included forced vital capacity and inspiratory capacity, peak expiratory flow, Breathlessness, Cough and Sputum Scale score, exercise capacity, quality of life (QoL), exacerbation assessments, safety and pharmacokinetics. Exploratory endpoints included inflammatory and tissue degradation biomarkers. A total of 838 patients were randomised to AZD9668 5 mg bid (212 patients), 20 mg bid (206 patients), 60 mg bid (202 patients) or placebo (218 patients). AZD9668 showed no effect on lung function, respiratory signs and symptoms, QoL or biomarkers. At end of treatment, the change in mean pre-bronchodilator FEV1 for AZD9668 60 mg bid compared with placebo was 0.00L (95% confidence interval: -0.05, 0.04; p = 0.873). Overall, AZD9668 was well tolerated; the numbers of patients with adverse events (AEs), serious AEs and AEs leading to discontinuation were similar in each of the four study groups. AZD9668 60 mg bid showed no clinical benefit and no effect on biomarkers of inflammation or tissue degradation when added to tiotropium in patients with COPD. These results raise important questions for future investigation of anti-inflammatory and disease-modifying agents in patients with COPD.
Authors:
Claus Vogelmeier; Teresita O Aquino; Christopher D O'Brien; John Perrett; Kulasiri A Gunawardena
Related Documents :
10929919 - A randomized, double-masked, clinical study of the efficacy of four nonsteroidal anti-i...
162669 - Diclofenac sodium (voltaren): results of a multi-centre comparative trial in adult-onse...
17651539 - The vioxx in prostate cancer prevention study: cardiovascular events observed in the ro...
22377729 - Altered cerebral vasoregulation predicts the outcome of patients with partial anterior ...
23395559 - Efficacy of orally applied probiotic capsules for bacterial vaginosis and other vaginal...
23210419 - Effectiveness of a new dentifrice with baking soda and peroxide in removing extrinsic s...
14501459 - Hearing loss after intratympanic gentamicin therapy for unilateral ménière's disease.
23874279 - The perils of global signal regression for group comparisons: a case study of autism sp...
7538239 - Impact of prostate size on the outcome of transurethral laser evaporation of the prosta...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  COPD     Volume:  9     ISSN:  1541-2563     ISO Abbreviation:  COPD     Publication Date:  2012 Apr 
Date Detail:
Created Date:  2012-03-30     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101211769     Medline TA:  COPD     Country:  England    
Other Details:
Languages:  eng     Pagination:  111-20     Citation Subset:  IM    
Affiliation:
1Universitätsklinikum Giessen und Marburg, Marburg, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Enrichment of extruded snack products with co-products from chestnut mushroom (Agrocybe aegerita) pr...
Next Document:  Effect of Bronchial Colonisation on Airway and Systemic Inflammation in Stable COPD.